Stockscreener 앱 받기
0.7971
0.37%
-0.003
시간 외 거래:
.81
0.0129
+1.62%
전일 마감가:
$0.8001
열려 있는:
$0.804
하루 거래량:
3.82M
Relative Volume:
0.19
시가총액:
$57.77M
수익:
-
순이익/손실:
$-33.36M
주가수익비율:
-1.1886
EPS:
-0.6706
순현금흐름:
$-23.09M
1주 성능:
-1.04%
1개월 성능:
+259.86%
6개월 성능:
+25.59%
1년 성능:
-22.61%
1일 변동 폭
$0.7805
$0.822
1주일 범위
$0.75
$0.995
52주 변동 폭
$0.1952
$1.55
Pds Biotechnology Corp Stock (PDSB) Company Profile
명칭
Pds Biotechnology Corp
전화
800-208-3343
주소
303A COLLEGE ROAD EAST, PRINCETON
Compare PDSB vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PDSB
Pds Biotechnology Corp
|
0.7971 | 57.77M | 0 | -33.36M | -23.09M | -0.6706 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pds Biotechnology Corp Stock (PDSB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-11-01 | 개시 | B. Riley Securities | Buy |
| 2021-06-28 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-11-10 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-05-27 | 개시 | Alliance Global Partners | Buy |
| 2020-03-09 | 개시 | Noble Capital Markets | Outperform |
| 2019-10-24 | 개시 | Chardan Capital Markets | Buy |
모두보기
Pds Biotechnology Corp 주식(PDSB)의 최신 뉴스
PDS Biotechnology Corporation (PDSB) Stock Price, News, Quote & History - Yahoo! Finance Canada
symbol__ Stock Quote Price and Forecast - cnn.com
PDS Biotechnology (NASDAQ: PDSB) Announces Phase 2 VERSATILE-002 Trial Results with 39.3-Month Median Survival - Kalkine Media
PDS Biotech reports 39.3-month survival data for HPV16 therapy By Investing.com - Investing.com Australia
PDS Biotech’s PDS0101 Shows 39.3-Month Median Survival in JAMA Oncology Publication - Minichart
PDS Biotech reports 39.3-month survival data for HPV16 therapy - Investing.com
PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncology - manilatimes.net
A head-and-neck cancer trial reported 39.3 months of median survival - Stock Titan
Patrick Soon-Shiong Secures Board Seat at PDS Biotechnology with 19.9% Stake - TradingView
PDS Biotechnology gets 19.9% Nant Capital stake | PDSB SEC FilingForm SCHEDULE 13D - Stock Titan
PDS Biotechnology updates corporate presentation highlighting PDS0301 clinical data and financing - tradingview.com
Patrick Soon-Shiong backs PDS Biotechnology (NASDAQ: PDSB) as cancer drugs move toward Phase 3 - Stock Titan
PDS Biotechnology Corporation (PDSB) Options ChainYahoo Finance - Yahoo! Finance Canada
PDS Biotechnology (PDSB) Stock Fair Value Moves Lower After Analyst Cuts And Financing Scrutiny - Yahoo Finance
PullBack Stocks PDSB, PRSO, IGC, RETO: Who Breaks First? - FinancialContent
PDS Biotech Stock Surges Tuesday: What's Driving the Action? - Benzinga
PDS Biotechnology jumps as investors react to PIPE closing and Patrick Soon-Shiong tie-up - Quiver Quantitative
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
PDS Biotechnology Closes $11.3 Million Initial PIPE Tranche Led by Nant Capital - Minichart
PDS Biotechnology Retires Debt and Secures New Financing - TipRanks
PDS Biotechnology Retires Yorkville $6M Note Early With $4.6M Redemption - TradingView
PDS Biotech Raises $11.3 Million in Initial PIPE Led by Patrick Soon-Shiong - citybiz
PDS Biotechnology Raises $11.3 Million in Initial Closing of PIPE Led by Nant Capital; Dr. Soon-Shiong Joins Board - quiverquant.com
Weekly Recap: Up to $22.55M PIPE and HC Wainwright cuts price target to $5 - TradingView
PDS Biotechnology Market Sentiment - Benzinga España
Most Active Stocks on September 8: PDS Biotech, Green Circle, Mobix Labs, Intel and Nokia Lead Volume - ChartMill
Curious about the most active stocks on Tuesday? - ChartMill
PDS Biotech soars as it announces up to $22.55 million financing - thepharmaletter.com
PDS Biotech Jumps as Soon-Shiong-Backed Financing Eases Funding Pressure - Quiver Quantitative
PDS Biotech raises up to USD 22.55m to advance IL-12 immunotherapy toward Phase III in CRC - AllSci
Dow Tumbles 450 Points; US Small Business Sentiment Declines In August - Benzinga
PDS Biotechnology Announces PIPE Financing and Strategic Alignment - TipRanks
PDS Biotech raises up to $22.55M led by Nant Capital - Investing.com Canada
Phase 3 trial plan could unlock $11M more for PDS Biotechnology (NASDAQ: PDSB) - Stock Titan
PDS Biotech Announces up to $22.55 Million Financing Led by Dr. Patrick Soon-Shiong, Founder of NantWorks - marketscreener.com
80% survived at least two years in a 22-patient trial of PDS Biotech's cancer treatment - Stock Titan
PDS Biotechnology’s Phase 3 Head and Neck Cancer Trial Termination: What It Means for Investors - TipRanks
PDS Biotech’s Lender Gets 100% of New Non-ATM Equity Cash - TechStock²
PDSB News | PDS BIOTECHNOLOGY CORP (NASDAQ:PDSB) - ChartMill
PDS Biotechnology Amends $6 Million Promissory Note, Tightening Repayment With YA II PN - TradingView
PDS Biotechnology (Nasdaq: PDSB) changes terms on a $6M loan - Stock Titan
Stephan Toutain removed as COO at PDS Biotechnology - TradingView
PDS Biotechnology (PDSB) to shed 36% of staff and part ways with COO - Stock Titan
PDS Biotechnology Corp (NASDAQ: PDSB) Share Price, PDSB Stock News, PDSB Share Price & Updates - Kalkine
Form 8K PDS Biotechnology Corp For: 19 August By Investing.com - Investing.com Nigeria
PDS Biotechnology announces CFO resignation and interim appointments - Investing.com
PDS Biotechnology CFO Lars Boesgaard to Resign; Janetta Trochimiuk and Frank Bedu-Addo Appointed Interim Officers - TradingView
PDS Biotechnology (NASDAQ: PDSB) CEO takes interim finance role as CFO departs - Stock Titan
Weekly Recap: PDS0301 Phase 2 results and Q2 adjusted loss $0.18 - TradingView
PDS Biotechnology shareholders approve charter amendment and director elections - Investing.com
Form 8K PDS Biotechnology Corp For: 14 August By Investing.com - Investing.com Nigeria
Pds Biotechnology Corp (PDSB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.06%
2.55%
자본화:
|
볼륨(24시간):